Therapy for β-globinopathies: A brief review and determinants for successful and safe correction

Abstract

Gene therapy for β-globinopathies, particularly β-thalassemia and sickle cell anemia, hold much promise for the future, as a one time cure for these common and debilitating disorders. Correction of the β-globinopathies using lentivirus vectors (LV) carrying the β- or γ-globin genes and elements of the locus control region has been well established in murine models, and a good idea of "what it will take to cure these diseases" has been developed in the first decade of the twenty-first century. A clinical trial using one such vector has been initiated in France while other trials are in development. Vector improvements to enhance the safety and efficiency of LV are being explored, while newer strategies, like homologous recombination in induced pluripotent cells for correction of sickle cell anemia, has been shown as a proof-of-concept. Here we provide a review of current progress in genetic correction of β-globin disorders. © 2010 New York Academy of Sciences.